TRACT Therapeutics
Blood & Organ Banks · Illinois, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
212 W Superior St Ste 130, Chicago, Illi...Phone Number
(312) 815-8993Website
www.tracttherapeutics.comRevenue
<$5 MillionIndustry
About TRACT Therapeutics
Singulera Therapeutics, Inc. is focused on developing a personalized regulatory T cell therapy platform, TRK-001, aimed at treating solid organ transplant patients and individuals with autoimmune disorders. The therapy utilizes patients' own regulatory T cells to establish immune tolerance, potentially preventing transplant rejection and reducing reliance on harmful immunosuppressive drugs. With significant clinical needs addressed, TRK-001 has shown early clinical success, including Orphan Drug Designation and promising results from Phase 1 trials. The company has established proprietary manufacturing methods and filed for patents in the U.S. and Europe.Explore more
TRACT Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to TRACT Therapeutics
Compare insights from companies similar to TRACT Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
TRACT Therapeutics Tech Stack
A closer look at the technologies used by TRACT Therapeutics
See more technologies
Top Blood & Organ Banks Companies
See more top companies
Frequently Asked Questions Regarding TRACT Therapeutics
Sign Up For FreeTo access detailed company insights
Singulera Therapeutics, Inc. is focused on developing a personalized regulatory T cell therapy platform, TRK-001, aimed at treating solid organ transplant patients and individuals with autoimmune disorders. The therapy utilizes patients' own regulatory T cells to establish immune tolerance, potentially preventing transplant rejection and reducing r... Read More
